PCSK9's role in kidney damage in nephrotic syndrome
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at how a protein called PCSK9 might affect kidney damage in people with nephrotic syndrome. It is for adults admitted to Kolding Hospital and aims to better understand the link between this protein and kidney problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must be a patient at Kolding Sygehus (Medical Department or Emergency Department).
- You cannot be taking PCSK9 inhibitors (a type of cholesterol drug).
- You must be willing to give informed consent.
- You should not have any serious health condition that prevents participation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests a keto-like supplement (Ketosteril) to help prevent or slow muscle loss in people with nephrotic syndrome. It may help by improving nutrition when the kidneys are leaking large amounts of protein.
This trial collects medical data and blood/urine samples from patients with minimal change disease or focal segmental glomerulosclerosis (FSGS) to better understand how the immune system damages kidney cells.
This research study looks at kidney diseases caused by the immune system—conditions where your body's defense system mistakenly attacks the kidneys. Researchers will study your medical history, blood, and urine to better understand these diseases and potentially improve treatment.
This study looks for specific proteins (autoantibodies) in your blood that may be linked to certain kidney diseases. It aims to better understand the immune system's role in minimal change disease and FSGS, which could lead to better treatments.
This study looks at children’s experiences and understanding of nephrotic syndrome using questionnaires. It aims to learn what helps families and children, which could improve care over time.
This study looks at how a natural enzyme in the body, called PCSK9, affects blood platelets. It compares healthy people to those with heart risk factors to see if the enzyme changes how platelets work.
Hear when a new Nephrotic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.